| 25-6287 |
Marcus Brent Fields v. Pfizer Inc., et al. |
Second Circuit |
2025-12-04 |
Pending |
corporate-ethics drug-development federal-violations pharmaceutical-liability regulatory-compliance securities-law |
a) Pfizer Defendands Knew there Courd ~ TO yotene Lot RA boy ,
Could ~ Cause more Sever and or Heard damage body orguns damage
eS pecially Ceeapmet Am… |
| 24-1210 |
Brent Andrew Brackett Arbogast v. Pfizer Inc., as Successor to Wyeth Pharmaceuticals, et al. |
First Circuit |
2025-05-29 |
Denied |
appellate-review civil-procedure due-process fair-labor-standards-act fifth-amendment rule-41-dismissal |
Does the Fifth Amendment require appellate courts to rule on a petitioner's briefed arguments and alleged facts rather than unraised theories and fact… |
| 24A609 |
Brent Andrew Brackett Arbogast v. Pfizer Inc., as Successor to Wyeth Pharmaceuticals, et al. |
First Circuit |
2024-12-19 |
Presumed Complete |
circuit-split due-process fair-labor-standards-act judicial-procedure res-judicata rule-41 |
Whether a federal appellate court can dismiss a plaintiff's claims by mischaracterizing their legal arguments and failing to address substantive due p… |
| 22-339 |
Pfizer Inc. v. Department of Health and Human Services, et al. |
Second Circuit |
2022-10-12 |
Denied |
advisory-opinion-process anti-kickback-statute criminal-intent healthcare-fraud medical-decision-making medicare mens-rea remuneration rule-of-lenity statutory-interpretation |
Whether the Anti-Kickback Statute is violated only if the person offering the remuneration intends to corrupt the recipient's medical decision-making |
| 20-74 |
Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director, United States Patent and Trademark Office v. Eugene H. Luoma, et al. |
Federal Circuit |
2020-07-27 |
GVR |
administrative-law america-invents-act enablement intellectual-property judicial-review obviousness patent-eligibility patent-review patent-trial-and-appeal-board patent-validity prior-art written-description |
Whether the Patent Trial and Appeal Board's application of the statutory requirements for patentability under 35 U.S.C. §§ 101, 102, 103, and 112 was … |
| 19-278 |
Pfizer Inc., et al. v. Superior Court of California, County of Los Angeles, et al. |
California |
2019-09-03 |
Denied |
bristol-myers-squibb civil-procedure due-process federal-courts federal-law forfeiture jurisdiction personal-jurisdiction subject-matter-jurisdiction |
Whether a defendant's efforts to establish federal subject matter jurisdiction can result in forfeiture of an otherwise fully preserved challenge to p… |
| 18-1578 |
Pfizer Inc. v. Alida Adamyan, et al. |
Ninth Circuit |
2019-06-25 |
Denied |
cafa-removal civil-procedure class-action-fairness-act diversity-jurisdiction federal-court joint-trial mass-action products-liability removal state-court state-court-proposal |
Whether a state court's proposal to try jointly the claims of more than 100 plaintiffs can qualify for 'mass action' removal under the Class Action Fa… |
| 18A980 |
Pfizer Inc. v. Alida Adamyan, et al. |
Ninth Circuit |
2019-03-28 |
Presumed Complete |
None |
|